breast cancer (non metastatic) clinical trials results

trastuzumab after chemotherapy versus control
HERA (BIG 01-01) 1-year, 2005
NCT00045032
one years of trastuzumab given every three weeks
versus
observation
patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy open
Follow-up duration: 2 years
trastuzumab during chemotherapy versus control
NSABP B-31,
same regimen plus 52 weeks of trastuzumab beginning with the first dose of paclitaxel
versus
doxorubicin and cyclophosphamide followed by paclitaxel every 3 weeks
Early-stage, node-positive invasive breast cancer
Follow-up duration: 2.9 years
NCCTG N9831(C vs A),
same regimen plus 52 weeks of trastuzumab initiated concomitantly with paclitaxel
versus
doxorubicin and cyclophosphamide followed by weekly paclitaxel
Early-stage invasive breast cancer, node positive or high-risk node negative (tumor 1 cm if HR negative or 2 cm if HR positive)
Follow-up duration: 2.9 years